This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Heartfailure (HF) is a highly prevalent long-term condition, with variation in services and resources across the UK. This report provides findings from a cross-sectional survey of community HF services in the UK between September 2021 and February 2022. Eighty-five responses describing community HF services were received.
This study sought to examine temporal trends in the clinical characteristics and inhospital occurrence of adverse outcomes of IE.Methods and ResultsUsing the Japan nationwide administrative database, we identified patients with IE in Japan from 2016 to 2021. per 100 000 population in 2021. A total of 17 407 patients with IE (37.8%
Despite proven benefits in reducing morbidity and mortality, many heartfailure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).
Heartfailure (HF) is a significant problem in the UK with variation in services across the country. Here we describe the findings from a cross-sectional survey of HF services in the UK performed between September 2021 and February 2022. The clinical lead in 82% of hospitals was a cardiologist with specialist interest in HF.
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
The peak in publications occurred in 2021, driven by the urgent need to understand the cardiovascular implications of COVID-19. Keyword analysis identified “COVID-19” and “SARS-CoV-2” as dominant themes, with related terms like myocarditis and heartfailure reflecting major cardiovascular concerns. and Guo T et al.
The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heartfailure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heartfailure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
Heartfailure with reduced ejection fraction (HFrEF) survey endorsed by the Council for Cardiology Practice and the HeartFailure Association of the European Society of Cardiology (ESC).
Aim The value of disease-modifying therapies (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and severe heartfailure symptoms has been debated. After 30 months of treatment, patients could join an ongoing LTE study to receive open-label tafamidis.
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
Methods We included adult patients who had undergone Fontan surgery for congenital heart disease and were pregnant between 1994 and 2021. We aimed to evaluate the immediate and long-term outcomes among these patients who were followed at our centre. We examined maternal and obstetric outcomes.
Integration of palliative care in the 2021 ESC and the 2022 AHA/ACC/HFSA heartfailure guidelines. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; HF, heartfailure; HFSA, HeartFailure Society of America; LD, limited; R, randomized.
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A.
From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heartfailure and a left ventricular ejection fraction (LVEF) greater than 40 percent, according to a study published online Nov. 16 to 18 in Chicago.
Methods Using the publicly accessible Centers for Medicare and Medicaid Services Medicare Part D database and the Open Payments Database, this study assessed associations between industry-sponsored meal payments to physician prescribers and total amounts of Medicare claims and spending for sacubitril/valsartan between 2015 and 2021.
Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included. Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.
Current Role of Digoxin in HeartFailure as Per Guidelines and DIGIT-HF trial of Digitoxin Use of digoxin in heartfailure has come down markedly over the past decades due to concerns of toxicity and availability of more effective medications. Eur Heart J. 2021 Sep 21;42(36):3599-3726. Eur J Heart Fail.
2021 May 21;23(5):740-747. However, advanced heartfailure therapy never means it can be achieved only by state-of-the-art technology. Cardiac failure management remains basically disciplined medical management and a holistic approach to improve the quality of life. Heart Rhythm. Epub 2021 Jul 29.
Sodium-glucose cotransporter 2 inhibitors have demonstrated positive effects in heartfailure (HF) patients. Data regarding dapagliflozin administration from 70 patients diagnosed with HF between December 2020 and November 2021 at a Japanese heart centre were analysed retrospectively.
AimsTo assess the barriers to guideline-directed medical therapy (GDMT) use in heartfailure (HF), diagnostic workup and general knowledge about HF among physicians in Sweden.MethodsA survey about the management of HF was sent to 828 Swedish physicians including general practitioners (GPs) and specialists during 2021–2022.
Background: The heartfailure (HF) virtual consultation (VC) is an eHealth tool for delivery of peer-to-peer specialist advice to general practitioners (GPs) to discuss HF diagnosis/management. Reults: Between 2015 and 2021, 1681 VC cases were discussed. The majority of cases were discussed from remote areas (75%).
Journal of the American Heart Association, Ahead of Print. BackgroundTelemedicine interventions (TMIs) for heartfailure (HF) can reduce hospitalizations and deaths. It is unclear if low literacy and limited access to technology in low and middleincome countries affect these benefits.
Introduction Heartfailure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. Treatment is complicated by side effects and comorbidities. Statistical significance is determined at p<0.05.
The following are key points to remember from a 2024 ACC Expert Consensus Decision Pathway for treatment of heartfailure with reduced ejection fraction (HFrEF), an update to the 2021 document.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular rehospitalisation in heartfailure with reduced ejection fraction (HFrEF) patients. A retrospective study of four hospitals in England involving 184 patients with HFrEF exacerbations between March 2021 and June 2022 was performed.
Objectives (1) Develop a programme theory of why, for whom and in what contexts integrated palliative care (PC) and heartfailure (HF) services work/do not work; (2) use the programme theory to co-produce with stakeholders, intervention strategies to inform best practice and future research.
Knowledge and application of European Society of Cardiology/HeartFailure Association (ESC/HFA) guidelines in the management of advanced heartfailure (HF). Respondents were categorized into heartfailure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs).
BACKGROUND:The absence of practice standards in vasoactive agent usage for acute decompensated heartfailure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. in 2021 (Ptrend<0.001). in 2021 or the proportion of phenotype-based utilization. in 2013 to 48.6%
Aims Heartfailure (HF) has a lower public profile compared with other serious health conditions, notably cancer. times that of the other conditions; annual cancer mortality is two times that caused by coronary heart disease (including HF) or dementia. times per million words (pmw), ‘dementia’ occurs 3.68
Background Currently, there is no head-to-head comparison of novel pharmacological treatments for heartfailure with reduced ejection fraction (HFrEF). Methods Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021.
Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heartfailure, which can have dire outcomes if not found early.
ABSTRACT Aims The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non-CV, in a large real-world heartfailure (HF) population across the ejection fraction (EF). Methods and Results Patients with HF from the Swedish HF Registry between 2000-2021 were included.
Abstract Aims The COVID-19 pandemic disrupted healthcare systems and possibly impacted the management of heartfailure (HF). This study examined the impact of the pandemic on HF hospitalization activities, outcomes, and costs in Victoria, Australia. Data were analysed using descriptive analysis and interrupted time series analysis.
Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heartfailure-related cardiogenic shock. ACHF-CS, acute-on-chronic failure-related cardiogenic shock; CI, confidence interval; DNHF-CS, de novo heartfailure-related cardiogenic shock; HR, hazard ratio.
By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. Secondary outcomes included rates of reoperation, infective endocarditis, stroke, and hospital admissions for heartfailure. The research team followed these patients for a median time of 2.4 years after TAVR and 4.9 for SAVR vs. 0.4%
Background:The prevalence of risk factors for heartfailure and outcomes varies across racial and ethnic groups. Despite this variation, treatment guidelines for heartfailure are standardized, potentially overlooking the unique needs and responses of minority populations.
Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heartfailure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.
As a result, healthcare faces rising expenses from frequent emergency room visits, lengthy hospital stays, costly procedures like stent placements and bypass surgeries, as well as the long-term management of chronic conditions like heartfailure (HF). billion between 2021 and 2023.
882 Dates Distributed: March 1, 2021 to present Date Initiated by Firm: March 13, 2024 Device Use The HeartMate 3 Left Ventricular Assist System (LVAS) is used to help the heart pump blood when it is not able to do so effectively on its own. .: Use of these devices may cause serious injury or death.
Objective To evaluate stress, depression and quality of life among community-dwelling patients with heartfailure (HF) and evaluate their effect on perceived medication adherence in a socioeconomically challenged setting.
Researchers analyze primary and secondary cardiovascular outcomes in 132,784 inpatients with COVID-19 (October 8, 2020 to September 30, 2021) and 31,173 inpatients with non-COVID-19 pneumonia (January 1, 2019 to December 31, 2019) in Korea. The results indicate a lower risk of cardiovascular disease in COVID-19 patients.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content